<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369785</url>
  </required_header>
  <id_info>
    <org_study_id>REBACCCWFU 91105</org_study_id>
    <secondary_id>U10CA081851</secondary_id>
    <nct_id>NCT00369785</nct_id>
  </id_info>
  <brief_title>Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors</brief_title>
  <official_title>Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Donepezil may help lessen confusion and fatigue and improve mood and quality of
      life in patients who have undergone radiation therapy for brain tumors. It is not yet known
      whether donepezil is more effective than a placebo in lessening side effects of radiation
      therapy in patients with brain tumors.

      PURPOSE: This randomized phase III trial is studying donepezil to see how well it works in
      lessening side effects of radiation therapy compared with a placebo in patients who have
      undergone radiation therapy for brain tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the effect of donepezil hydrochloride vs placebo, in terms of improving
           neurocognitive symptom cluster (i.e., cognitive impairment, subjective confusion, and
           fatigue), in patients who have undergone partial- or whole-brain irradiation for brain
           tumors.

      Secondary

        -  Compare the effect of these regimens on mood and quality of life in these patients.

      OUTLINE: This is a prospective, double-blind, placebo-controlled, randomized, multicenter
      study. Patients are stratified according to prior brain irradiation type (whole-brain vs
      partial-brain) and study site. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral donepezil hydrochloride once or twice daily for up to 24
           weeks in the absence of unacceptable toxicity.

        -  Arm II: Patients receive oral placebo once or twice daily for up to 24 weeks in the
           absence of unacceptable toxicity.

      Patients complete self-reported questionnaires (quality of life, fatigue, subjective
      confusion, neurocognitive battery, and mood) at baseline and 12 and 24 weeks.

      PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Memory as Quantified by HVLT-immediate Recall</measure>
    <time_frame>24 weeks</time_frame>
    <description>Memory is quantified using the Hopkins Verbal Learning Test (HVLT) - immediate recall. Participants are asked to recall 12 words. Each recalled word is given one point. They are given three trials. The total score is the sum of the recalled words. The range for HVLT-Immediate recall is 0 to 36. Higher scores represent better memory.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Memory as Quantified by the HVLT-discrimination</measure>
    <time_frame>24 weeks</time_frame>
    <description>In the Hopkins Verbal Learning Test - discrimination, participants are given lists of 12 correct words and 12 incorrect words. HVLT-discrimination is the number of correctly recognized words minus the number incorrectly recognized. The range for this outcome measure is -12 to 12. Higher scores represent better memory.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Brain Tumors</condition>
  <condition>Metastatic Disease</condition>
  <arm_group>
    <arm_group_label>Arm I - Donepezil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II - Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil hydrochloride</intervention_name>
    <description>Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily</description>
    <arm_group_label>Arm I - Donepezil</arm_group_label>
    <other_name>Donepezil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day</description>
    <arm_group_label>Arm II - Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Adults &gt;18 years old.

          -  Life expectancy of at least &gt; 30 weeks.

          -  Must have received a prior course of at least 30 Gy fractionated whole or partial
             brain irradiation for treatment of a primary brain tumor or metastatic disease to the
             brain.

          -  Must have completed radiation &gt; 6 months prior to enrollment and have no radiographic
             evidence of brain disease, or stable brain disease defined as no evidence of tumor
             progression in the 3 months prior to enrollment.

          -  Patients who have undergone one or more treatments with single fraction stereotactic
             radiosurgery (SRS) in addition to whole or partial brain irradiation are eligible, as
             long as the SRS was completed &gt; 6 months prior to registration if NED or stable
             disease.

          -  Radiation treatment records must be available for all prior radiation treatments
             (external beam and/or SRS).

          -  Patients who have received PCI (prophylactic cranial irradiation) are eligible.

          -  Karnofsky Performance Status must be &gt; 60 or ECOG 0-2.

          -  Treatment with steroids, anti-cholinergics, anti-epileptics, anti-depressants, and /or
             sedatives/benzodiazepines is acceptable, but the patient must be on a stable or
             decreasing dose at the time of study entry.

          -  Patients using narcotic analgesics on a stable dose and/or prn basis are eligible.

          -  Patients currently on a stable dose of Methylphenidate or Dextramphetamine are
             eligible.

          -  For patients with brain metastases, if extracranial primary or metastatic disease is
             present, it must have responded to local and/or systemic treatment. Must be stable in
             the 3 months prior to enrollment.

          -  Must not be receiving chemotherapy at the time of enrollment.

          -  Patient must not have any planned therapy, including surgery, brain radiation of any
             type, chemotherapy, or immunotherapy during the next 30 weeks for brain or
             extracranial primary metastatic disease.

          -  Hormonal therapy for patients with breast or prostate cancer is acceptable.

          -  Breast patients receiving therapy with Herceptin are allowed.

          -  Patients must be able to give informed consent to participate in the study, including
             signing the consent form.

          -  Patients must have a telephone.

        EXCLUSION CRITERIA:

          -  Patients cannot be currently taking dementia drugs, cognitive enhancers, neuroleptics,
             and/or anti-parkinsonian agents. For patients who have used these drugs in the past,
             they must not have used them in the 2 weeks prior to enrolling on the study.

          -  Hypersensitivity to donepezil.

          -  Patients may not currently be taking Ketoconazole or Quindine

          -  Arrythmias including bradycardia or heartblock

          -  Patients who have received, GliaSite or other type of brain brachytherapy, (Gliadel
             Wafers permitted) convection enhanced delivery of immunotoxins, and/or any other
             investigational modalities for treatment of their brain tumor. The effects of
             donepezil on the developing human fetus at the recommended therapeutic dose are
             unknown. For this reason, women of child-bearing potential and men must agree to use
             adequate contraception (hormonal or barrier method of birth control; abstinence) prior
             to study entry and for the duration of study participation. Should a woman become
             pregnant or suspect she is pregnant while participating in this study, she should
             inform her treating physician immediately.

          -  It is unknown whether donepezil is excreted in breast milk, for this reason women who
             are currently breast-feeding are not eligible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Rapp, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Associates in Womens Health, PA - North Review</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Medical Arts Tower</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Cancer Center at Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Maine Comprehensive Cancer Center at Central Maine Medical Center</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology - Hematology, PA - Hooksett</name>
      <address>
        <city>Hooksett</city>
        <state>New Hampshire</state>
        <zip>03106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakes Region General Hospital</name>
      <address>
        <city>Laconia</city>
        <state>New Hampshire</state>
        <zip>03246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Don Monti Comprehensive Cancer Center at North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - MeritCare Hospital</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity CancerCare Center</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Center for Cancer Care at Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44309-2090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Cancer Care Center at MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United States Air Force Medical Center - Wright-Patterson</name>
      <address>
        <city>Wright-Patterson Air Force Base</city>
        <state>Ohio</state>
        <zip>45433-5529</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thompson Cancer Survival Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Center for Cancer and Blood</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <results_first_submitted>July 15, 2015</results_first_submitted>
  <results_first_submitted_qc>January 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2017</results_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive/functional effects</keyword>
  <keyword>fatigue</keyword>
  <keyword>psychosocial effects of cancer and its treatment</keyword>
  <keyword>radiation toxicity</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>adult choroid plexus tumor</keyword>
  <keyword>adult craniopharyngioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult anaplastic meningioma</keyword>
  <keyword>meningeal melanocytoma</keyword>
  <keyword>adult meningeal hemangiopericytoma</keyword>
  <keyword>adult grade I meningioma</keyword>
  <keyword>adult grade II meningioma</keyword>
  <keyword>adult grade III meningioma</keyword>
  <keyword>adult papillary meningioma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult pineoblastoma</keyword>
  <keyword>adult pineocytoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult supratentorial primitive neuroectodermal tumor (PNET)</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult ependymoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult subependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were accrued between 2/2008 and 12/2011 at NCI CCOP sites across the nation.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I - Donepezil</title>
          <description>Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day
donepezil hydrochloride: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily</description>
        </group>
        <group group_id="P2">
          <title>Arm II - Control</title>
          <description>Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day
Placebo: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never started</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Multiple reasons</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized patients</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I - Donepezil</title>
          <description>Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day
donepezil hydrochloride: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily</description>
        </group>
        <group group_id="B2">
          <title>Arm II - Control</title>
          <description>Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day
Placebo: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="99"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="155"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" lower_limit="19" upper_limit="84"/>
                    <measurement group_id="B2" value="54.9" lower_limit="19" upper_limit="81"/>
                    <measurement group_id="B3" value="55.1" lower_limit="19" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Memory as Quantified by HVLT-immediate Recall</title>
        <description>Memory is quantified using the Hopkins Verbal Learning Test (HVLT) - immediate recall. Participants are asked to recall 12 words. Each recalled word is given one point. They are given three trials. The total score is the sum of the recalled words. The range for HVLT-Immediate recall is 0 to 36. Higher scores represent better memory.</description>
        <time_frame>24 weeks</time_frame>
        <population>Participants with 24 week HVLT data.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Donepezil</title>
            <description>Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day
donepezil hydrochloride: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Control</title>
            <description>Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day
Placebo: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day</description>
          </group>
        </group_list>
        <measure>
          <title>Memory as Quantified by HVLT-immediate Recall</title>
          <description>Memory is quantified using the Hopkins Verbal Learning Test (HVLT) - immediate recall. Participants are asked to recall 12 words. Each recalled word is given one point. They are given three trials. The total score is the sum of the recalled words. The range for HVLT-Immediate recall is 0 to 36. Higher scores represent better memory.</description>
          <population>Participants with 24 week HVLT data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" spread="0.45"/>
                    <measurement group_id="O2" value="22.2" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference in immediate recall memory at 24 weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.62</p_value>
            <p_value_desc>Not adjusted for multiple comparisons.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Memory as Quantified by the HVLT-discrimination</title>
        <description>In the Hopkins Verbal Learning Test - discrimination, participants are given lists of 12 correct words and 12 incorrect words. HVLT-discrimination is the number of correctly recognized words minus the number incorrectly recognized. The range for this outcome measure is -12 to 12. Higher scores represent better memory.</description>
        <time_frame>24 weeks</time_frame>
        <population>Number of participants with 24 week memory data</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Donepezil</title>
            <description>Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day
donepezil hydrochloride: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Control</title>
            <description>Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day
Placebo: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day</description>
          </group>
        </group_list>
        <measure>
          <title>Memory as Quantified by the HVLT-discrimination</title>
          <description>In the Hopkins Verbal Learning Test - discrimination, participants are given lists of 12 correct words and 12 incorrect words. HVLT-discrimination is the number of correctly recognized words minus the number incorrectly recognized. The range for this outcome measure is -12 to 12. Higher scores represent better memory.</description>
          <population>Number of participants with 24 week memory data</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="0.24"/>
                    <measurement group_id="O2" value="9.2" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference in discrimination memory between the two groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.007</p_value>
            <p_value_desc>Not adjusted for multiple comparisons.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <desc>Analysis includes everyone with post-treatment AE/toxicity data.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I - Donepezil</title>
          <description>Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day
donepezil hydrochloride: Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily</description>
        </group>
        <group group_id="E2">
          <title>Arm II - Control</title>
          <description>Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day
Placebo: Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Ear - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hearing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dental: teeth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Dental: peridontal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Muscle Cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial: CN II Vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Neuropathy: cranial: CN VII Motor-face; Sensory-taste</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Pain: Back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive Disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Mood Alteration: Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="96"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="96"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="81" subjects_affected="43" subjects_at_risk="96"/>
                <counts group_id="E2" events="70" subjects_affected="36" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="105" subjects_affected="55" subjects_at_risk="96"/>
                <counts group_id="E2" events="122" subjects_affected="61" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Muscle Cramps</sub_title>
                <counts group_id="E1" events="58" subjects_affected="32" subjects_at_risk="96"/>
                <counts group_id="E2" events="48" subjects_affected="26" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="70" subjects_affected="42" subjects_at_risk="96"/>
                <counts group_id="E2" events="73" subjects_affected="40" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="83" subjects_affected="34" subjects_at_risk="96"/>
                <counts group_id="E2" events="91" subjects_affected="34" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="21" subjects_at_risk="96"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Cognitive Disturbance</sub_title>
                <counts group_id="E1" events="64" subjects_affected="26" subjects_at_risk="96"/>
                <counts group_id="E2" events="73" subjects_affected="28" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Doug Case</name_or_title>
      <organization>Wake Forest NCORP Research Base</organization>
      <phone>(336) 716-1048</phone>
      <email>dcase@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

